[go: up one dir, main page]

MX2010003948A - N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas. - Google Patents

N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas.

Info

Publication number
MX2010003948A
MX2010003948A MX2010003948A MX2010003948A MX2010003948A MX 2010003948 A MX2010003948 A MX 2010003948A MX 2010003948 A MX2010003948 A MX 2010003948A MX 2010003948 A MX2010003948 A MX 2010003948A MX 2010003948 A MX2010003948 A MX 2010003948A
Authority
MX
Mexico
Prior art keywords
phenyl
substituted
therapeutic use
bipyrrolidine
ureas
Prior art date
Application number
MX2010003948A
Other languages
English (en)
Inventor
Siegfried Stengelin
Lothar Schwink
William J Hurst
Zhongli Gao
Werngard Czechtizky
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2010003948A publication Critical patent/MX2010003948A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invenci?n describe y reivindica una serie de N-fenil-bipirrolidin ureas sustituidas de f?rmula (I). (ver f?rmula I) en la que R, R1, R2, R3, R4 y R5 son como se describen en la presente memoria. M?s espec?ficamente, los compuestos de esta invenci?n son moduladores de los receptores H3 y, por lo tanto, son ?tiles como agentes farmac?uticos, especialmente en el tratamiento y/o prevenci?n de una variedad de enfermedades moduladas por los receptores H3, incluyendo enfermedades asociadas con el sistema nervioso central. Adem?s, la presente invenci?n tambi?n describe m?todos para la preparaci?n de N-fenil-bipirrolidin urcas sustituidas e intermedios para ello.
MX2010003948A 2007-10-17 2008-10-14 N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas. MX2010003948A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98060607P 2007-10-17 2007-10-17
PCT/US2008/079763 WO2009052068A1 (en) 2007-10-17 2008-10-14 Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof

Publications (1)

Publication Number Publication Date
MX2010003948A true MX2010003948A (es) 2010-04-30

Family

ID=40248052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003948A MX2010003948A (es) 2007-10-17 2008-10-14 N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas.

Country Status (24)

Country Link
US (1) US8222290B2 (es)
EP (1) EP2215058B1 (es)
JP (1) JP5380455B2 (es)
KR (1) KR20100082349A (es)
CN (1) CN101903341B (es)
AT (1) ATE534625T1 (es)
AU (1) AU2008312641A1 (es)
CA (1) CA2702933C (es)
CY (1) CY1112391T1 (es)
DK (1) DK2215058T3 (es)
ES (1) ES2378011T3 (es)
HR (1) HRP20120166T1 (es)
IL (1) IL205002A0 (es)
MA (1) MA31889B1 (es)
MX (1) MX2010003948A (es)
MY (1) MY148807A (es)
NZ (1) NZ584692A (es)
PL (1) PL2215058T3 (es)
PT (1) PT2215058E (es)
RS (1) RS52221B (es)
RU (1) RU2478094C2 (es)
SI (1) SI2215058T1 (es)
WO (1) WO2009052068A1 (es)
ZA (1) ZA201002114B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0818626A2 (pt) 2007-10-17 2015-09-29 Sanofi Aventis n-fenil-bipirrolidina carboxamidas substituída e uso terapêutico da mesma
SI2212283T1 (sl) 2007-10-17 2011-12-30 Sanofi Sa Substituirani n-fenil-bipirolidin karboksamidi in njihova terapevtska uporaba
AU2008312636B2 (en) * 2007-10-17 2013-03-14 Sanofi-Aventis Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine H3 receptor modulators
KR20090129927A (ko) 2008-06-13 2009-12-17 주식회사 엘지화학 발열체 및 이의 제조방법
US10412788B2 (en) 2008-06-13 2019-09-10 Lg Chem, Ltd. Heating element and manufacturing method thereof
US9611171B2 (en) * 2008-06-13 2017-04-04 Lg Chem, Ltd. Heating element and manufacturing method thereof
AR083718A1 (es) 2010-05-11 2013-03-20 Sanofi Aventis Fenil cicloalquil pirrolidina (piperidina) espirolactamas y amidas sustituidas, preparacion y uso terapeutico de las mismas
JP5833105B2 (ja) 2010-05-11 2015-12-16 サノフイ 置換ｎ−ヘテロアリールスピロラクタムビピロリジン類、その製造及び治療的使用
WO2011143162A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
EP2569296A1 (en) * 2010-05-11 2013-03-20 Sanofi Substituted n-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof
TW201206444A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
JP5766278B2 (ja) 2010-05-11 2015-08-19 サノフイ 置換されたｎ−アルキルおよびｎ−アシルテトラヒドロ−イソキノリン誘導体、それらの製造および治療上の使用
TW201206910A (en) * 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
AU2011329233A1 (en) * 2010-11-15 2013-05-23 Abbvie Deutschland Gmbh & Co Kg NAMPT and ROCK inhibitors
US9079888B2 (en) * 2011-02-23 2015-07-14 Suven Life Sciences Limited Compounds as histamine H3 receptor ligands

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
CA2504272A1 (en) * 2002-10-23 2004-05-06 Janssen Pharmaceutica, N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101142180B (zh) 2005-03-17 2011-05-04 伊莱利利公司 作为组胺h3受体拮抗剂的吡咯烷衍生物
CA2602234C (en) * 2005-04-01 2014-01-14 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
WO2007005503A1 (en) * 2005-07-01 2007-01-11 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
WO2007048595A1 (en) * 2005-10-27 2007-05-03 Ucb Pharma, S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
BRPI0818626A2 (pt) 2007-10-17 2015-09-29 Sanofi Aventis n-fenil-bipirrolidina carboxamidas substituída e uso terapêutico da mesma
AU2008312636B2 (en) 2007-10-17 2013-03-14 Sanofi-Aventis Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine H3 receptor modulators
SI2212283T1 (sl) 2007-10-17 2011-12-30 Sanofi Sa Substituirani n-fenil-bipirolidin karboksamidi in njihova terapevtska uporaba

Also Published As

Publication number Publication date
EP2215058B1 (en) 2011-11-23
HRP20120166T1 (hr) 2012-03-31
CY1112391T1 (el) 2015-12-09
PL2215058T3 (pl) 2012-04-30
AU2008312641A1 (en) 2009-04-23
ATE534625T1 (de) 2011-12-15
NZ584692A (en) 2011-12-22
CN101903341A (zh) 2010-12-01
MA31889B1 (fr) 2010-12-01
CA2702933C (en) 2012-12-18
WO2009052068A1 (en) 2009-04-23
JP2011500697A (ja) 2011-01-06
ES2378011T3 (es) 2012-04-04
KR20100082349A (ko) 2010-07-16
US20100173908A1 (en) 2010-07-08
PT2215058E (pt) 2012-03-06
US8222290B2 (en) 2012-07-17
DK2215058T3 (da) 2012-03-12
SI2215058T1 (sl) 2012-03-30
EP2215058A1 (en) 2010-08-11
CN101903341B (zh) 2012-10-03
RS52221B (sr) 2012-10-31
RU2010119554A (ru) 2011-11-27
ZA201002114B (en) 2010-12-29
MY148807A (en) 2013-05-31
JP5380455B2 (ja) 2014-01-08
CA2702933A1 (en) 2009-04-23
RU2478094C2 (ru) 2013-03-27
HK1146056A1 (en) 2011-05-13
IL205002A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
MX2010003949A (es) N-fenil-bipirrolidina carboxamidas sustituidas y uso terapeutico de las mismas.
MX2010003948A (es) N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas.
MY149650A (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
MX2010004003A (es) N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
TN2011000233A1 (en) Substituted piperidine spiro pyrrolidinone and piperidinones used as h3 modulators
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
UA104880C2 (uk) Заміщені тетрагідропіранспіропіролідинон і тетрагідропіранспіропіперидинон, спосіб їх одержання й застосування в лікувальних цілях
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
MX2010004311A (es) Productos intermedios de moduladores de gamma-secretasa.
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren
TN2010000373A1 (en) The present invention provides oxadiazoanthracene

Legal Events

Date Code Title Description
FG Grant or registration